The National Pharmaceutical Council recently caught up with Allergy and Asthma Network (AAN) CEO and President Tonya Winders about her role in the Institute for Clinical and Economic Review’s (ICER) assessments on allergy and asthma drugs.
Winders said she was “ill-prepared” for her first ICER review some years ago, but became significantly more engaged and active for later reviews. ANN, she added, also works to keep its members in the loop about ICER, too.
“We also keep our members, who include patients, families, caregivers and health care providers, aware of what ICER is and how we are working on their behalf at each stage of the review process,” Winders said.
To read the full discussion on NPC’s blog, click here.